Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGA | O60502 | 1/20 | 0.35 |
| ▸ | FGF1 | P05230 | 1/20 | 0.32 |
| ▸ | FBP1 | P09467 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24282178 | 0.84 | L3MBTL1 (0.42) | OGAFGF1 | |
| SCHEMBL17370176 | 0.84 | G6PD (0.32) | OGA | |
| SCHEMBL19901913 | 0.83 | OGA (0.37) | OGAFBP1 | |
| SCHEMBL15631938 | 0.79 | OGA (0.37) | OGAFGF1FBP1 | |
| SCHEMBL27383297 | 0.79 | OGA (0.37) | OGAFGF1FBP1 | |
| SCHEMBL8217821 | 0.79 | OGA (0.37) | OGAFGF1FBP1 | |
| SCHEMBL264356 | 0.78 | LGALS8 (0.43) | OGA | |
| SCHEMBL7155276 | 0.78 | FGF1 (0.45) | OGAFGF1FBP1 | |
| SCHEMBL7154153 | 0.78 | FGF1 (0.45) | OGAFGF1FBP1 | |
| SCHEMBL15907822 | 0.78 | OGA (0.36) | OGAFGF1FBP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210205226-A1 | ORAL DRUG DOSAGE FORM COMPRISING DRUG IN THE FORM OF NANOPARTICLES | Triastek, Inc. (CN) | 2021-07-08 | — | — | US | disclosed |
| US-10973767-B2 | Oral drug dosage form comprising drug in the form of nanoparticles | Triastek, Inc. (CN) | 2021-04-13 | — | — | US | disclosed |
| US-20200315971-A1 | 3D PRINTING METHODS FOR COMPARTMENTED PHARMACEUTICAL DOSAGE FORMS | Triastek, Inc. (CN) | 2020-10-08 | — | — | US | disclosed |
| US-20190321299-A1 | ORAL DRUG DOSAGE FORM COMPRISING VARIOUS RELEASE PROFILES | Triastek, Inc. (CN) | 2019-10-24 | — | — | US | disclosed |
| US-10363220-B2 | Compartmented pharmaceutical dosage forms | Triastek, Inc. (CN) | 2019-07-30 | — | — | US | disclosed |
| US-20190192440-A1 | ORAL DRUG DOSAGE FORM COMPRISING DRUG IN THE FORM OF NANOPARTICLES | Triastek, Inc. (CN) | 2019-06-27 | — | — | US | disclosed |
| US-10258575-B2 | Oral drug dosage forms having desired drug release profiles and uses thereof | Triastek, Inc. (CN) | 2019-04-16 | — | — | US | disclosed |
| US-9873715-B2 | Macrolides useful as anticancer agents | PIERRE FABRE MEDICAMENT (FR) | 2018-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10973767-B2 | Oral drug dosage form comprising drug in the form of nanoparticles | CYP2D6, CYP3A5, CYP3A7 | OGA 1765/4885FGF1 3721/4885FBP1 800/4885 |
| US-20190192440-A1 | ORAL DRUG DOSAGE FORM COMPRISING DRUG IN THE FORM OF NANOPARTICLES | CYP2D6, CYP3A5, CYP3A7 | OGA 1765/4885FGF1 3721/4885FBP1 800/4885 |
| US-10363220-B2 | Compartmented pharmaceutical dosage forms | CYP2D6, CYP3A5, CYP2F1 | OGA 2707/4885FGF1 1522/4885FBP1 315/4885 |
| US-20190321299-A1 | ORAL DRUG DOSAGE FORM COMPRISING VARIOUS RELEASE PROFILES | CYP2D6, CYP3A7, CYP3A5 | OGA 1844/4885FGF1 3101/4885FBP1 416/4885 |
| US-10258575-B2 | Oral drug dosage forms having desired drug release profiles and uses thereof | CYP2D6, CYP3A5, CYP3A7 | OGA 1632/4885FGF1 2713/4885FBP1 528/4885 |
| US-20200315971-A1 | 3D PRINTING METHODS FOR COMPARTMENTED PHARMACEUTICAL DOSAGE FORMS | CYP3A43, HTR3D, CYP3A7 | OGA 4337/4885FGF1 599/4885FBP1 1325/4885 |
| US-20210205226-A1 | ORAL DRUG DOSAGE FORM COMPRISING DRUG IN THE FORM OF NANOPARTICLES | CYP2D6, CYP3A5, CYP3A7 | OGA 1765/4885FGF1 3721/4885FBP1 800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.